Clinical trial
STRIVES: Status-Neutral TeleHealth Concierge Intervention for Unhoused People Who Use Drugs Via Engagement Through Street Medicine
NCT07931612 is registered in ClinicalTrials.gov with University of Miami as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- STRIVES: Status-Neutral TeleHealth Concierge Intervention for Unhoused People Who Use Drugs Via Engagement Through Street Medicine
- Lead sponsor
- University of Miami
- Phase
- Not applicable
- Overall status
- Not yet recruiting
- Start date
- May 1, 2027
- Completion date
- July 1, 2030
- Enrollment
- 200 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
hepatitis c (hcv), hiv, homelessness, substance use disorder (sud)
Arms
As registered; 2 arms.
-
Standard of Care Group (Off-site clinic referral and patient navigation)
Participants in this arm receive standard patient navigation and referral services for healthcare and social support needs for one year.
-
Status-Neutral Telehealth Concierge (SN-THR) Group
Participants in this arm receive the SN-THR intervention, a multidisciplinary street medicine and telehealth program providing integrated medical care, behavioral health services, care coordination, and social support for one year.
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Antiretroviral Adherence for Treatment/Prevention
Proportion of participants adherent to Antiretroviral Therapy (ART) for HIV treatment/prevention. HIV treatment adherence (ART adherence) will be defined by HIV RNA level \<200 copies/mL for PWH. PrEP adherence will be defined by any of the following: Dried Blood Spot (DBS) tenofovir diphosphate (TFV-DP) level of 700 fmol/punch for tenofovir disoproxil fumarate (TDF); DBS TFV-DP level of 950 fmol/punch for tenofovir alafenamide (TAF); or documentation of long-acting ART/PrEP (cabotegravir injection in the previous 8 weeks or lenacapavir injection in the previous 6 months) via EHR abstraction.
Lead sponsor's other trials
University of Miami, most recent start first.
+836 more trials See the organization page
Similar trials
Same condition (Hepatitis C) and phase, most recent start first.
+261 more trials See the condition page